|
|
|
|
|
IN THIS ARTICLE   
The elderly need to drink at least 8 servings of water or equivalent liquids every day. more...  OTHER TOPICS |
Scleroderma Meggan Mackay, M.D., M.S., and Peter Barland, M.D. Dr. Mackay is an Assistant Professor of Medicine at Albert Einstein College of Medicine. Drs. Mackay and Barland report no conflict of interest. "...one of the most terrible of all human ills [is] to wither slowly...and be 'beaten down and marred and wasted' until one is literally a mummy, encased in an ever-shrinking, slowly contracting skin of steel, [it] is a fate not pictured in any tragedy, ancient or modern"1 Hard and tight skin, most often on the face and hands, is the most prominent feature of scleroderma. Also known as Systematic Sclerosis (SSc) and sometimes characterized as the "disease that turns people into stone," scleroderma is especially frightening because we do not know what causes it. The word "scleroderma" comes from two ancient Greek words: "sclero," meaning hard, and "derma," meaning skin. Yet despite its name, scleroderma can also damage internal tissues and organs and it is this damage which is far more dangerous to a person's health than changes in the skin. On the positive side, medical researchers have made progress. Better treatments are now available for some of the symptoms of SSc. And, the disease does not appear to be contagious, infectious, cancerous or malignant in any way. Thankfully, SSc is also rare -- affecting approximately 300,000 persons in the United States -- although not as rare as better known diseases such as ALS, or Lou Gehrig's Disease, which affects about 30,000 Americans in an average year. What Exactly is Scleroderma? SSc is a so-called autoimmune -- your body reacting against itself -- disorder that affects any of three systems: the immune system, the vascular system and the body's connective tissue. Its classic sign is fibrosis, where too much fiber tissue is formed. This is what causes SSc's hardening effect on the skin. Some types of scleroderma are more severe than others. A diagnosis certainly does not mean a death sentence and the disease does not progress relentlessly in all cases. Scleroderma is more common in women than in men and is found in all age groups, though it usually first occurs between the ages of 25 and 55. How is SSc Detected? Finding out that a person has scleroderma can be a long and frustrating journey. Part of the reason for this is that few doctors see many cases of SSc. Another reason is that the medical definition of SSc is so complex, involving many symptoms that may appear at different times in different forms in different people. And in the early stages, SSc is easily mistaken for other connective tissue diseases, such as systemic lupus erythematosus, polymyositis and rheumatoid arthritis. Uncertainty and frustration take a toll on the psychological well-being of SSc sufferers, who often describe the period before they are diagnosed as the most difficult part of the illness. To give an idea of the vagueness and complexity of SSc, in 1980 the American College of Rheumatology defined it as the presence of a specific type of skin hardening near the metacarpal phalangeal (MCP) joints of the hand, or two of the following:2
The main feature that distinguishes dcSSc from CREST is the extent to which it affects the skin.3 While both cause skin thickening on the hands and face, dcSSc causes skin thickness on the upper arms, thighs and torso as well. (Figures 1, 2). Figure 1. Diffuse Cutaneous Scleroderma.  Note the taught, shiny skin over the face and chest, and how the lips have lighter pigmentation (hypopigmentation) and are pursed. Figure 2. Diffuse Cutaneous Scleroderma.  Note the extensive skin changes on the back. Figure 3. CREST Syndrome.  Along with tightened, shiny skin over the face, there are widespread telangectasias, or dilated blood vessels, creating numerous red spots on the skin, and a tightened mouth opening. The two types of scleroderma are different in other ways as well. DcSSc tends to be a more aggressive disease, with more and stronger symptoms early on. The typical first sign of dcSSc is Raynaud's Syndrome, followed within a year by skin thickening, especially of the hands; overall fatigue; and joint problems. People suffering from dcSSc are more likely than those with CREST to go on to develop lung, kidney, gastrointestinal and heart problems.4 CREST progresses more slowly; sufferers sometimes have Raynaud's for many years before any skin changes. They are also far less likely ever to develop internal organ problems.5 This difference in how they affect the body's internal organs explains the great difference in mortality rates between the two types of SSc. There is a five-year mortality rate of approximately 30-40% for dcSSc, as compared to only 20% for CREST.6,7,8 Who Is at Risk? For reasons that are not well understood, women are much more likely to develop SSc, by a factor of almost four to one. The incidence of the disease also varies by country and region, from rates of 3.7 cases per million people per year in Britain and Iceland to 18.7-22.8 cases per million per year in the United States.9,10,11,12,13 The average age at which sufferers first contract the disease varies by ethnicity and race. Whites typically develop their first symptoms in their 30s or 40s; while African Americans tend to be at least a decade younger. The racial differences are striking. Not only is SSc considerably more prevalent in African Americans than whites, but in African Americans the disease is almost twice as likely to be more severe and aggressive.14 Understandably, the first reaction of those who are told that they have this disease is: "Why me?" That is an important question, one which medical science is vigorously trying to answer.15,16,17 Some research has suggested possible genetic causes or predispositions for SSc.18,19,20,21 Interestingly, however, studies of twins have not shed any light on this question. The research on SSc echoes a recurring theme in autoimmune diseases -- that while genetic susceptibility may be a prerequisite for the disease, it is probably not the only factor in determining whether or not someone gets the disease.22,23 Most researchers feel that SSc is triggered by some environmental insult to the system of someone who is already susceptible, whether for genetic or other reasons. What kind of insult is not clear, despite epidemiological studies that have implicated exposure to some types of chemical solvents, silica dust and silicone implants.24,25,26,27,28,29,30 The fact that geographic "clusters" of SSc have been identified in England, in Italy and among the Choctaw Indians in Oklahoma provides strong evidence for the "environmental trigger" theory.31 More About the Two Types of SSc The progress of SSc can be quite different, depending on the type of scleroderma a person has. Those with early dcSSc tend to suffer from fatigue, joint pain and stiffness, weight loss, and "puffy" hands and feet, before or along with Raynaud's and skin thickening. The progression of skin thickening is rapid in dcSSc, usually peaking within two to three years and then beginning to recede. Figure 4. Digital Pitting.  Note how the fingertips have lost their fat pads and appear pitted. Internal organ damage is far more common in dcSSc than in CREST. Most of those with dcSSc who will go on to develop internal organ problems do so in the first three years of the disease. For example, in one study of dcSSc sufferers who developed kidney disease, 75% did so within three years of diagnosis and only 5% in the six years afterward. Mortality rates correlate directly with the location and extent of organ damage. The three-year survival rates for dcSSc break down as follows: 25% for those with severe damage to the gastrointestinal tract; 50% for those with lung damage; 55% for those with kidney damage; and 60% for those with heart damage. The good news for those with SSc and kidney problems is that Scleroderma renal crisis, a serious kidney condition, is now very treatable with a class of drugs known as ACE inhibitors.32 When dcSSc affects the lungs, it does so in three ways, by causing what is known as interstitial lung disease (ILD) with fibrosis (22%), pulmonary hypertension (19%), or both.33,34 Pulmonary hypertension is a blood vessel disorder in the lung that produces shortness of breath, chest pain, dizzy spells and fainting. It is inevitable that most SSc sufferers will have gastrointestinal problems at some point. Virtually all will develop reflux disease, which causes stomach acid to regurgitate up into the throat. 8% of those with dcSSc will go on to develop more severe pseudo-obstruction and malabsorption conditions of the large or small intestines. These can progress to the point where the victims can no longer eat. Myocardial fibrosis, or the development of excess fibrous tissue around the heart, occurs in 15% of dcSSc patients.35,36 Because people with CREST have fewer and less severe internal organ problems than those with dcSSc, they have a better overall outcome. CREST often progresses slowly and with subtle skin changes that are preceded for years by Raynaud's. Renal crisis and serious lung disease are virtually unheard of in CREST. Esophageal reflux disease is common in CREST but severe gastrointestinal problems such as malabsorption are not. Long-standing Raynaud's, telangectasias and calcinosis are classic hallmarks of the disease. Figures 3 and 5 demonstrate the facial telangectasias characteristic of CREST. Figure 5. Sclerodactyly.  The skin over the hands and forearms is very tight and thickened. Finally, not surprisingly, depression is common in people with SSc, occurring in about half of all cases.37 What Treatments Are There for SSc? With most connective tissue diseases, the standard medical approach is to use immunosuppressive agents (for example, steroids) to combat abnormal immune responses such as inflammation. This has not been successful in SSc, perhaps because inflammation plays such a minor role in this disease. The exceptions would be the relatively uncommon SSc symptoms of arthritis; pericarditis, or inflammation of the tissues around the heart; and alveolitis, or inflammation of the tooth socket. Steroids, methotrexate and other immunosuppressive drugs can help with these symptoms.38,39,40 Pulmonary hypertension is extremely difficult to treat. Infusions of the drugs iloprost or epoprostanol can be effective but they are prohibitively expensive and difficult to administer.41,42,43,44 Calcium channel blocker drugs are somewhat useful, but only in a minority of cases. Test results for the recently approved drug Bosentan®, however, are extremely promising.45,46 Despite much effort and research, there are unfortunately no good treatments for skin thickening. The only reassurance for those with dcSSc is that the worst will be over after about two years.47,48,49,50,51,52 The best treatment for chronic reflux disease is the use of proton pump inhibitor drugs, which block the body's production of stomach acid. There are currently no good treatments for small intestine malabsorption caused by SSc, other than, if it comes to that, providing nutrition through a feeding tube or IV. Raynaud's Syndrome is another difficult to treat SSc symptom. Calcium channel blocker drugs help only a little with Raynaud's.53 Iloprost does seem to help reduce the frequency and severity of Raynaud's attacks.54,55 Conclusions The current state of our knowledge of Scleroderma (SSc) is this -- despite recent progress in the areas of molecular immunology and molecular biology that promises one day to unravel the secrets of this disease, SSc remains incurable. Some types of SSc, however, are worse than others and many of its symptoms are treatable to varying degrees. This includes pulmonary hypertension and scleroderma renal crisis, once one of the most life-threatening aspects of SSc.
References 1. Osler,W.: On diffuse scleroderma; with special reference to diagnosis and the use of thyroid-gland extract. J. Cutan. Genito-urin. Dis. 16: 49, 127, 1898. return 2. Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90. return 3. LeRoy EC, Black CM, Fleichmajer R, et al. Scleroderma (systemic sclerosis). Classification, subset and pathogenesis. J. Rheumatol. 1988; 15: 202-5. return 4. Steen VD, MedsgerTA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44. return 5. Stupi AM, Steen VD, Medsger TA, et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis. Arthritis Rheum 1986; 29: 515-24. return 6. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 40: 734-42. return 7. Bulpit KJ, Clements PJ, Lachenbruch PA et al. Early undifferentiated connective tissue disease: Outcome and prognostic indicators in early scleroderma. Ann Intern Med 1993; 118: 602-9. return 8. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am.1996 Nov;22(4):675-94. return 9. Medsger TA, Masi AT, Rodnan GP, et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75: 369-76. return 10. Michet Jr CJ, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue disease in Rochester Minnesota, 1950 through 1979. Mayo Clin Proc 1985; 60:105-13. return 11. Steen VD, Oddis CV, Conte CG, et al. Incidence of Systemic sclerosis in Alleghany County, Pennsylvania. A twenty-year study of hospital-diagnosed A twenty year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997; 40: 441-5. return 12. Maricq HR, Weinrich MC, Keil JE, et al. Prevalence of scleraderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989; 32: 998-1006. return 13. Mayes M, Laing T, Gillespie B, et al. Prevalence, incidence and survival rates of systemic sclerosis in the Detroit Metropolitan area. Arthritis Rheum 1996; 39(suppl):S150. return 14. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246-55. return 15. Tan FK, Arnett FC. Genetic factors in the etiology of systemic sclerosis and raynaud phenomenon. Curr Opin Rheumatol 2000; 12:511-19. return 16. Gilchrist FC, Bunn C, Foley PJ, et al. Class II HLA associations with antibodies in sclerodermaP a highly significant role for HLA-DP. Genes Immun 2001; 2: 76-81. return 17. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003; 48: 1956-63. return 18. Tan FK, Wang N, Kuwana M, et al. Association of fibrillin I single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001; 44: 893-901. return 19. Hitraya EG, Varga J, Artlett CM, et al. Identification of elements in the promoter region of the alpha (1) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 1998; 41: 2048-58. return 20. Hata R, Akai J, Kimura A, et al. Association of functional microsatellites in the human type 1 collagen alpha 2 chain (COL 1 A2) gene with systemic sclerosis. Biochem Biophys Res Commun 2000; 272: 36-40. return 21. Avila JJ, Lympany PA, Pantelidis P, et al. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999; 20:106-12. return 22. Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, Bean M, Ober C, Bianchi DW. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998; 351: 559-62. return 23. Artlett CM, Smith B, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998; 338: 1186-91. return 24. Parks CG, Conrad K, Cooper GS. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 1999; 107 (suppl 5): 793-802. return 25. Silman AJ, Jones S. What is the contibution of environmental factors to the occurrence of scleroderma in men? Ann Rheum Dis 1992; 51: 1322-24. return 26. Burns CJ, Laing TJ, Gillespie BW, et al. The epidemiology of scleroderma among women: assessment of risk factors from exposure to silicone and silica. J Rheumatol 1996; 23: 1904-11. return 27. Katsuri KN, Hatakyama A, Speira H, et al. Antifibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes. J Exp Med 1995; 181:1027-36. return 28. Maul CG, Jimenez SA, Riggs E, et al. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase 1: sequence similarity with retroviral p30 gag protein suggesting a possible cause for autoimmunity in systemic sclerosis. Proc Nat Acad Sci USA 1989; 86: 8492-96. return 29. Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med. 2000; 6: 1183-6. return 30. Jimenez SA, Diaz A, Khalili K. Retroviruses and the pathogenesis of systemic scslerosis. Int Rev Immunol. 1995; 12: 159-75. return 31. Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Arthritis Rheum 1996; 39: 1362-70. return 32. De Marco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum. 2002; 46: 2983-9. return 33. Diot, E, Giraudeau, B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 116:715. return 34. Briggs DC, Vaughan RW, Eelsh KI, et al. Immunologic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 661-2. return 35. Byers RJ, Marshall DAS, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 1997; 56: 393-94. return 36. D'Angelo, Fries JF, Masi AT. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-40. return 37. Matsura E, Ohta A, Kanegae F, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003; 30: 1782-87. return 38. White B, Moore WC, Wrigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54. return 39. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-36. return 40. Steen VD, Lanz Jr JK, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37:1290-96. return 41. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostanol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425-34. return 42. Caramaschi P, Biasi D, Ferrari M, et al. Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions. Rheumatol Int 2004. return 43. Paramoythayan NS, Lasserson TJ, Wells AU, Walters EH. Prostacyclin for pulmonary hypertension. Cochrane Database Syst Rev. 2002;(3):CD002994. return 44. Oleschewski H, Simonneau G, Nazzareno G, et al. Inhaled Iloprost for the treatment of severe pulmonary hypertension. N Eng J Med 2002; 347:322-29. return 45. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Eng J Med 2002; 346: 896-903. return 46. Channick RN, Simmoneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: 1119-23. return 47. Clements J, Furst DE, Weng-Kee W, et al. High dose versus low-dose penicillamine in early diffuse systemic sclerosis. Arthritis Rheum 1999; 42:1194-1203. return 48. Siebold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. Ann Inter Med 2000; 132: 871-79. return 49. Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-72. return 50. Pope J, Bellamy N, Seibold J, et al. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-58. return 51. Bazzichi L, Rossi A, De Giorgio F, et al. Clinical improvement in systemic sclerosis resulting from urokinase therapy explained by light and electron microscopy skin examination. Scand J Rheumatol 2003; 32: 261-67. return 52. Mayes MD, O'Donnell D, Rothfield NF, et al. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004; 50: 553-57. return 53. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44: 1841-47. return 54. Bettoni L, Geri A, Airo P, et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rhuematol 2002; 21: 244-50. return 55. Black CM, Halkier-Sorensen L, Belch JJ, et al. Oral iloprost in raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, dose-comparison study. Br J Rheumatol 1998; 37:952-60. return |
|||||
|
|
|
 |
||||
|
NEWS SEARCH CONTENTS MEDITORIAL ASK DISCUSS REGISTER HELP HOME |
||||||
© 2008 interMDnet Corporation. All Rights Reserved. PRIVACY POLICY |
||||||